A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors
This article was originally published in Pharmaceutical Approvals Monthly
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.
You may also be interested in...
Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health
Emerging Company Profile: The company applies its mid-stage in-licensing strategy to bring in novel products for female contraception and sexual arousal disorder.
Will Palatin's Phase III Female Sex Endpoint Swap Pass With FDA?
Palatin plans to file the drug for FDA approval in the second half of 2017, but a change in the co-primary endpoint presents a complication.
FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs
Draft guidance says 'associated distress' may replace number of satisfying sexual events as a co-primary efficacy endpoint.